Ann: ********* Investor Presentation, page-14

haha we can dream indeed....

yes, no fear of a deal being done for quite a while. In addition to the performance options at $1.79... If you read JPM and SVB healthcare industry reports. Acquisitions are happening much later in the road map. Less risk to acquirers. There's a LOT of work to be done with the bio chip as you know. We have to have some successful pathogen or virus or DNA detection by the gFETs. News of that alone should be a big boost to confidence of market, potential customers and the sp. Will get it over $1.50 in my opinion. I can dream that news will happen this year....after which they can refine, add more targets to detection list, refine some more. Then more testing and validation....which can all incrementally boost sp and increase the biochip IP value. The granting of patents can happen anywhere along this journey.